Related Experiment Video
Updated: May 14, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Omega-3 in antiarrhythmic therapy : cons position
1Division of Internal Medicine, University of Bologna, Sant'Orsola Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy. claudio.borghi@unibo.it
Insights
Omega-3 fatty acids
Area of Science:
- Cardiovascular research
- Clinical pharmacology
- Nutritional science
Background:
- The clinical impact of omega-3 (n-3 polyunsaturated fatty acids) on cardiovascular disease outcomes, particularly its antiarrhythmic effects and mechanisms, remains unclear.
- Epidemiological studies suggest reduced sudden cardiac death incidence with omega-3-rich diets or fish consumption over the past 15 years.
- Proposed antiarrhythmic mechanisms involve modulating myocyte ion channels and reducing excitability in ischemic myocardial tissue, though experimental results vary.
Purpose of the Study:
- To evaluate the association between omega-3 fatty acids and clinical outcomes in cardiovascular disease patients.
- To clarify the antiarrhythmic effects and mechanisms of omega-3 fatty acids.
- To assess the role of omega-3 in preventing sudden cardiac death and arrhythmias.
Main Methods:
- Review of epidemiological studies and clinical trials evaluating omega-3 intake or supplementation in cardiovascular patients.
- Analysis of experimental studies investigating the electrophysiological effects of omega-3 on cardiac myocytes.
- Examination of meta-analyses and specific randomized clinical trials, including GISSI-Prevenzione.
Main Results:
- While some meta-analyses show a reduction in cardiac death, evidence for omega-3 preventing sudden cardiac death is controversial and inconsistent across studies.
- Omega-3 may play a role in preventing cardiovascular mortality via multiple mechanisms, warranting investigation alongside other cardiovascular drugs.
- Omega-3 appears more effective in preventing atrial tachyarrhythmias, such as atrial fibrillation, than ventricular arrhythmias.
Conclusions:
- The antiarrhythmic effect of omega-3 fatty acids is not definitively established.
- Further research is essential to elucidate the precise role of omega-3 in preventing cardiac mortality, especially compared to arrhythmic death.
- Investigating omega-3's interaction with other cardiovascular medications is crucial for understanding its overall clinical benefit.
Abstract:
The association between omega-3 (n-3 polyunsaturated fatty acids) and the clinical outcome of patients with cardiovascular diseases such as coronary heart disease is currently unclear, especially regarding its possible antiarrhythmic effects and the not quite understood mechanisms of action. In the last 15 years, several epidemiological studies have shown a lower incidence of sudden cardiac death with a diet rich in omega-3 or fish consumption. The antiarrhythmic properties related to omega-3 have been related to modulation of sodium-dependent ion channels or sodium-calcium exchangers of myocytes through a reduction of their excitability especially in ischaemic or damaged myocardial tissue. However, the results of experimental studies have not always been consistent. Although the role of omega-3 in preventing sudden cardiac death has been evaluated in several clinical trials that included patients with coronary artery disease (particularly in patients with post-myocardial infarction), the interpretation of such data must be treated with extreme caution. In particular, while a reduction in cardiac death was demonstrated by a meta-analysis of several randomized clinical trials, a reduced risk of sudden cardiac death has been described only in the GISSI-Prevenzione study, while in other studies the evidence that emerged is more controversial, with wide confidence intervals that support the possibility of heterogeneity in the distribution of the factors involved in the efficacy of treatment. Omega-3 is probably involved in the prevention of cardiovascular mortality through different mechanisms, and it is crucial to study its association with other drugs such as ACE inhibitors or calcium channel blockers. The study of antiarrhythmic drugs has been divided into prevention of supraventricular and ventricular arrhythmias. In these conditions, the role of omega-3 seems to be more pronounced in atrial tachyarrhythmias such as atrial fibrillation, but does not have a role in ventricular arrhythmias. In summary, the antiarrhythmic effect of omega-3 is not clearly evident and further studies are needed to investigate its beneficial effect in cardiac mortality compared with arrhythmic death.
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Heart Failure Drugs: Inotropic Agents
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
